CHA AI Healthkare Reduces Convertible Bond Issuance to 2.5 Billion Won with Improved Terms, but Related Party Transaction and Dilution Risks Remain
CHA AI Healthkare corrected its convertible bond issuance decision, reducing the total face value from 5 billion won to 2.5 billion won and significantly improving borrowing terms by lowering the coupon rate from 5% to 0% and the maturity yield from 9% to 1%.
The conversion price is set at 12,463 won per share, well above the current market price of 6,530 won, but a monthly adjustment clause could lower it to a minimum of 8,725 won, creating potential future dilution risk.
The bonds are privately placed to a related party, CHA Careus, whose largest shareholder is CHA Biotech, raising governance concerns due to the related party transaction.
The proceeds will be used for investment purposes in 2026, with no specific high-ROI project disclosed.
Including existing 36th series convertible bonds of 40 billion won, total potential conversion shares amount to 4,708,183 shares, representing 25.86% of outstanding shares, posing significant overhang risk.
[AI Summary]CHA AI Healthkare improved terms on a convertible bond issuance to a related party, but governance risk and massive potential dilution from existing bonds weigh on shareholder value. The low-cost funding provides flexibility, yet the lack of transformative investment and possible downward conversion adjustments warrant caution.
KOSPI Filing Information
[Correction of Description] Report on Major Matters (Decision on Issuance of Convertible Bonds)